Representative before the EPO

Employment test 11 - 50 employees
Company dna eip1
operating since 2009
1002.25
Headquarter in London and 4 offices
active in Legal Services and IP Consulting

We have observed 19 EP applications Andrew John Sharples has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after December 14, 2012). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP11734227

STATIN THERAPY MONITORED BY GALECTIN- 3 MEASUREMENT

IPC classification:
A61K 31/505, A61P 9/00, G01N 33/50
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12783456

RESTRICTED IMMUNOGLOBULIN HEAVY CHAIN MICE

IPC classification:
A01K 67/027, C07K 16/46, C12N 15/85
Applicant:
Regeneron Pharmaceuticals Inc
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
The patent has been granted
EP11835162

CHLAMYDIA ANTIGENS AND USES THEREOF

IPC classification:
A61K 39/118
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
EXAMINATION IN PROGRESS
EP12736908

VACCINES AND COMPOSITIONS AGAINST STREPTOCOCCUS PNEUMONIAE

IPC classification:
A61K 38/00, A61K 39/09
Applicant:
Children's Medical Center Corporation
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
EXAMINATION IN PROGRESS
EP11787442

MULTIVALENT SYNTHETIC NANOCARRIER VACCINES

IPC classification:
A61K 9/51, A61K 31/4745, A61K 31/7115, A61K 33/06, A61K 39/00, A61K 39/385, A61K 39/39, A61K 45/06, A61K 47/02, A61K 47/22, A61K 47/24, A61K 47/48, A61P 25/34, A61P 31/04, A61P 31/10, A61P 31/12, A61P 35/00, A61P 37/04
Applicant:
Selecta Biosciences Inc
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
The patent has been granted
EP11787447

DOSE SELECTION OF ADJUVANTED SYNTHETIC NANOCARRIERS

IPC classification:
A61K 9/51, A61K 31/4745, A61K 31/7115, A61K 33/06, A61K 39/00, A61K 39/385, A61K 39/39, A61K 45/06, A61K 47/02, A61K 47/22, A61K 47/24, A61K 47/48, A61P 25/34, A61P 31/04, A61P 31/10, A61P 31/12, A61P 35/00, A61P 37/04
Applicant:
Selecta Biosciences Inc
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
EXAMINATION IN PROGRESS
EP12718709

PYRROLIDINE DERIVATIVES AS SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF

IPC classification:
A61K 31/40, A61K 31/401, A61P 9/10, A61P 11/06, A61P 25/28, A61P 37/00, C07D 207/12, C07D 207/16
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12716750

METHODS FOR PREPARATION OF MACROCYCLIC POLYESTER OLIGOMER VIA HETEROGENEOUS CATALYSIS

IPC classification:
B01J 21/06, B01J 21/08, B01J 37/02, C08G 63/183, C08G 63/81, C08G 63/85
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13746382

COLD BLOCK WITH EMBEDDED CHAMBERED BEVERAGE TAP

IPC classification:
B67D 1/04
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
GRANT OF PATENT INTENDED
EP11787434

NANOCARRIER COMPOSITIONS WITH UNCOUPLED ADJUVANT

IPC classification:
A61K 9/51, A61K 31/4745, A61K 31/7115, A61K 33/06, A61K 39/00, A61K 39/385, A61K 39/39, A61K 45/00, A61K 45/06, A61K 47/00, A61K 47/02, A61K 47/22, A61K 47/24, A61K 47/48
Applicant:
Selecta Biosciences Inc
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
EXAMINATION IN PROGRESS
EP12795905

HUMANIZED IL-6 AND IL-6 RECEPTOR

IPC classification:
A01K 67/027, C07K 14/54, C07K 14/715
Applicant:
Regeneron Pharmaceuticals Inc
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11195369

Herbal therapy for the treatment of asthma

IPC classification:
A61K 35/00, A61K 36/074, A61K 36/484, A61K 36/489, A61K 45/06
Agent:
Deborah Mary Hart, Kilburn & Strode LLP
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12178807

Herbal therapy for the treatment of food allergy

IPC classification:
A61K 36/074, A61K 36/185, A61K 36/232, A61K 36/258, A61K 36/54, A61K 36/718, A61K 36/736, A61K 36/756, A61K 36/758, A61K 36/9068, A61P 37/08
Agent:
Deborah Mary Hart, Kilburn & Strode LLP
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11728027

COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE

IPC classification:
A61K 31/4164, A61K 31/424, A61K 31/4365, A61K 31/437, A61K 31/4439, A61K 31/546, A61K 31/74, A61K 35/741, A61K 35/747, A61K 36/064, A61K 38/14, A61K 39/395, A61K 45/06, A61P 31/04
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11838881

MODIFIED NICOTINIC COMPOUNDS AND RELATED METHODS

IPC classification:
A01N 43/40, A61K 31/44, A61K 39/00, A61K 39/385, A61K 47/48
Applicant:
Selecta Biosciences Inc
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
EXAMINATION REQUESTED
EP11715092

BALANCED MYRISTATE- AND LAURATE-CONTAINING EDIBLE OIL

IPC classification:
A23D 7/00, A23D 9/00, A23L 1/29, A23L 1/30
Applicant:
Brandeis University
Agent:
Andrew John Sharples, EIP Europe LLP
Agent:
Høiberg A/S
Status:
PATENT GRANTED
EP12193602

Cell carrier and cell carrier containment devices containing regenerative cells

IPC classification:
A61K 35/28, A61K 35/32
Agent:
Zacco Denmark A/S
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
PATENT GRANTED
EP11842681

LATERAL FLOW IMMUNOASSAY FOR COMPLEMENT ACTIVATION AND METHODS OF USE FOR POINT-OF-CARE ASSESSMENT OF COMPLEMENT-ASSOCIATED DISORDERS

IPC classification:
G01N 33/558, G01N 33/86
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12704188

USE OF GALECTIN-3 FOR DETECTING AND PROGNOSING HEART FAILURE AFTER ACUTE CORONARY SYNDROME

IPC classification:
G01N 33/566, G01N 33/68
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN

Please Sign in to use this feature